ORBi: Rouers A. - Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Carcinomatosis : Higher Complication Rate for Oxaliplatin Compared to Mitomycin C

Reference : Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Perit...


	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Surgery
	To cite this reference:	http://hdl.handle.net/2268/81973

Title :	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Carcinomatosis : Higher Complication Rate for Oxaliplatin Compared to Mitomycin C
Language :	English
Author, co-author :	Rouers, A. [> >]
	Laurent, S. [> >]
	Detroz, Bernard [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie abdominale- endocrinienne et de transplantation >]
	Meurisse, Michel [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie abdominale- endocrinienne et de transplantation >]
Publication date :	2006
Journal title :	Acta Chirurgica Belgica
Publisher :	Acta Medica Belgica
Volume :	106
Pages :	302-306
Audience :	National
ISSN :	0001-5458
City :	Bruxelles
Country :	Belgique
Keywords :	[en] Cytoreductive surgery ; hyperthermic intraperitoneal chemotherapy ; peritoneal carcinomatosis
	[fr] colorectal cancer ; oxaliplatin ; mitomycin C.
Abstract :	[en] Peritoneal carcinomatosis (PC) from colo-rectal cancer carries a very poor prognosis with a mean and median overall survival times of 6.9 and 5.2 months. It has been proved that a locoregional therapeutic approach of this disease with cytoreduction followed by hyperthermic intraperitoneal chemotherapy (HIPEC) improved survival of these patients. However, this combined treatment presents a high complication rate. Methods : 21 patients with PC of colorectal origin underwent complete cytoreduction followed by HIPEC using Mitomycin-C (13 patients) or oxaliplatin (8 patients) and the open coliseum technique. For each case the medical datas were retrospectively analysed to determine feasibility, morbidity, mortality, survival time and prognostic factors. Results : All patients presented a Sugarbaker’s Peritoneal Cancer index inferior to 15. The mean operating time was 453 minutes. After a median follow-up of 24.9 months, actuarial disease-free survival was 36.6% at 5 years. The median survival time was 34 months. The morbidity rate was 33.3% with a significant higher complication rate in the oxaliplatin group (5/8) than in the Mytomycin-C (MMC) group (2/13). One patient (4.7%) died two months after treatment with MMC (endocarditis). Conclusions : This series confirm positive impact of cytoreduction and HIPEC on PC. We obtained a moderated complications rate thanks to a high degree of selection of the patient. Oxaliplatin scheme is responsible of a higher morbidity than in MMC group. Phase III trial comparing these two drugs is needed.
Target :	Professionals ; Students ; General public
Permalink :	http://hdl.handle.net/2268/81973

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Open access	rouers(1).pdf		Publisher postprint	66.7 kB	View/Open

All documents in ORBi are protected by a user license.

Dspace v1.5